Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma
- PMID: 34094902
- PMCID: PMC8175980
- DOI: 10.3389/fonc.2021.616625
Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma
Abstract
Targeting androgen receptor (AR) has been shown to be promising in treating glioblastoma (GBM) in cell culture and flank implant models but the mechanisms remain unclear. AR antagonists including enzalutamide are available for treating prostate cancer patients in clinic and can pass the blood-brain barrier, thus are potentially good candidates for GBM treatment but have not been tested in GBM orthotopically. Our current studies confirmed that in patients, a majority of GBM tumors overexpress AR in both genders. Enzalutamide inhibited the proliferation of GBM cells both in vitro and in vivo. Although confocal microscopy demonstrated that AR is expressed but not specifically in glioma cancer stem cells (CSCs) (CD133+), enzalutamide treatment significantly decreased CSC population in cultured monolayer cells and spheroids, suppressed tumor sphere-forming capacity of GBM cells, and downregulated CSC gene expression at mRNA and protein levels in a dose- and time-dependent manner. We have, for the first time, demonstrated that enzalutamide treatment decreased the density of CSCs in vivo and improved survival in an orthotopic GBM mouse model. We conclude that AR antagonists potently target glioma CSCs in addition to suppressing the overall proliferation of GBM cells as a mechanism supporting their repurposing for clinical applications treating GBM.
Keywords: AR antagonist; androgen receptor; cancer stem cells; enzalutamide; glioblastoma.
Copyright © 2021 Zhao, Wang, Ahmed, Liu, Zhang, Cathcart, DiMaio, Punsoni, Guan, Zhou, Wang, Batra, Bronich, Hei, Lin and Zhang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8175980/bin/fonc-11-616625-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8175980/bin/fonc-11-616625-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8175980/bin/fonc-11-616625-g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8175980/bin/fonc-11-616625-g004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8175980/bin/fonc-11-616625-g005.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8175980/bin/fonc-11-616625-g006.gif)
![Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8175980/bin/fonc-11-616625-g007.gif)
Similar articles
-
Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).Int J Mol Med. 2018 Aug;42(2):691-702. doi: 10.3892/ijmm.2018.3668. Epub 2018 May 10. Int J Mol Med. 2018. PMID: 29749540 Free PMC article. Review.
-
Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.J Chin Med Assoc. 2016 Oct;79(10):538-45. doi: 10.1016/j.jcma.2016.03.010. Epub 2016 Aug 13. J Chin Med Assoc. 2016. PMID: 27530866
-
Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.J Neurosurg. 2017 May;126(5):1448-1460. doi: 10.3171/2016.1.JNS152077. Epub 2016 Jul 15. J Neurosurg. 2017. PMID: 27419830 Free PMC article.
-
Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.Biochem Biophys Res Commun. 2015 Dec 18;468(3):485-9. doi: 10.1016/j.bbrc.2015.06.137. Epub 2015 Jun 24. Biochem Biophys Res Commun. 2015. PMID: 26116770 Free PMC article. Review.
-
Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.Biomaterials. 2012 Feb;33(5):1462-76. doi: 10.1016/j.biomaterials.2011.10.071. Epub 2011 Nov 17. Biomaterials. 2012. PMID: 22098779
Cited by
-
Androgen loss weakens anti-tumor immunity and accelerates brain tumor growth.Res Sq [Preprint]. 2024 Mar 29:rs.3.rs-4014556. doi: 10.21203/rs.3.rs-4014556/v1. Res Sq. 2024. PMID: 38585839 Free PMC article. Preprint.
-
Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics.Cancer Metastasis Rev. 2024 Mar;43(1):321-362. doi: 10.1007/s10555-024-10171-0. Epub 2024 Mar 22. Cancer Metastasis Rev. 2024. PMID: 38517618 Review.
-
RBM24 Suppresses the Tumorigenesis of Glioblastoma by Stabilizing LATS1 mRNA.Biochem Genet. 2024 Mar 18. doi: 10.1007/s10528-024-10715-7. Online ahead of print. Biochem Genet. 2024. PMID: 38499965
-
Androgen deficiency is associated with a better prognosis in glioblastoma.Eur J Med Res. 2024 Jan 17;29(1):57. doi: 10.1186/s40001-024-01648-3. Eur J Med Res. 2024. PMID: 38233838 Free PMC article.
-
Intracranial Assessment of Androgen Receptor Antagonists in Mice Bearing Human Glioblastoma Implants.Int J Mol Sci. 2023 Dec 26;25(1):332. doi: 10.3390/ijms25010332. Int J Mol Sci. 2023. PMID: 38203506 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Research Materials